XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.21.2

Net Income (Loss) Per Share Attributable to Common Shareholders (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Earnings Per Share [Abstract] |
Schedule of basic and diluted net loss per share |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Numerator : |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) attributable to common shareholders – Basic |  | $ | 28,944 |  |  | $ | (10,295 | ) |  | $ | (14,163 | ) |  | $ | (20,055 | )
Less interest expense on potentially dilutive convertible notes payable |  | $ | 196 |  |  | $ | - |  |  | $ | - |  |  | $ | - |
Net income (loss) attributable to common shareholders - Diluted |  | $ | 29,140 |  |  | $ | (10,295 | ) |  | $ | (14,163 | ) |  | $ | (20,055 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average common shares outstanding –Basic |  |  | 62,071,754 |  |  |  | 17,358,159 |  |  |  | 61,307,699 |  |  |  | 17,358,159 |
Weighted average effect of potentially dilutive securities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Effect of potentially dilutive stock options |  |  | 5,791,023 |  |  |  | - |  |  |  | - |  |  |  | - |
Effect of potentially dilutive common stock warrants |  |  | 1,485,049 |  |  |  | - |  |  |  | - |  |  |  | - |
Effect of potentially dilutive convertible notes payable |  |  | 482,703 |  |  |  | - |  |  |  | - |  |  |  | - |
Effect of potentially dilutive restricted stock awards |  |  | 208,105 |  |  |  | - |  |  |  | - |  |  |  | - |
Weighted average common shares outstanding –Diluted |  |  | 70,038,634 |  |  |  | 17,358,159 |  |  |  | 61,307,699 |  |  |  | 17,358,159 |
Net income (loss) per share attributable to common shareholders: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.47 |  |  | $ | (0.59 | ) |  | $ | (0.23 | ) |  | $ | (1.16 | )
Diluted |  | $ | 0.42 |  |  | $ | (0.59 | ) |  | $ | (0.23 | ) |  | $ | (1.16 | )
Schedule of securities excluded from computation of diluted net income (loss) per share |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Series D redeemable convertible preferred stock |  |  | - |  |  |  | 9,394,057 |  |  |  | - |  |  |  | 9,394,057 |
Series C redeemable convertible preferred stock |  |  | - |  |  |  | 7,264,519 |  |  |  | - |  |  |  | 7,264,519 |
Series B redeemable convertible preferred stock |  |  | - |  |  |  | 4,168,815 |  |  |  | - |  |  |  | 4,168,815 |
Series A redeemable convertible preferred stock |  |  | - |  |  |  | 16,066,503 |  |  |  | - |  |  |  | 16,066,503 |
Series D redeemable convertible preferred stock warrants |  |  | - |  |  |  | 320,441 |  |  |  | - |  |  |  | 320,441 |
Series A redeemable convertible preferred stock warrants |  |  | - |  |  |  | 1,608,670 |  |  |  | - |  |  |  | 1,608,670 |
Convertible notes payable (see Note 11) |  |  | - |  |  |  | - |  |  |  | 482,703 |  |  |  | - |
Common stock warrants (see Note 10) |  |  | 2,523,351 |  |  |  | - |  |  |  | 4,569,962 |  |  |  | - |
Options to purchase common stock |  |  | 2,685,575 |  |  |  | 7,509,810 |  |  |  | 9,063,423 |  |  |  | 7,509,810 |
Restricted stock awards |  |  | 1,100,050 |  |  |  | - |  |  |  | 1,245,489 |  |  |  | - |
Chardan Unit Purchase Option Warrants (see Notes 3 and 10) |  |  | 24,583 |  |  |  | - |  |  |  | 24,583 |  |  |  | - |
Clene Nanomedicine contingent earn-out shares (see Note 3 and 12) |  |  | 8,346,185 |  |  |  | - |  |  |  | 8,346,185 |  |  |  | - |
Initial Shareholders contingent earn-out shares (see Note 3 and 12) |  |  | 750,000 |  |  |  | - |  |  |  | 750,000 |  |  |  | - |
Total |  |  | 15,429,744 |  |  |  | 46,332,815 |  |  |  | 24,482,345 |  |  |  | 46,332,815 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration